Department of Biology, University of Asmara, Asmara, Eritrea,1 Department of Microbiology and Tumor Biology-MTC, Clinical Microbiology, Karolinska Institute, Karolinska Hospital L2:02, Stockholm SE-17176, Sweden2
Received 9 March 2005/ Returned for modification 30 April 2005/ Accepted 28 May 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Adequate knowledge of the dynamics of emm types in a region may shed light on the pathogenesis of GAS infections and is crucial for selecting appropriate vaccine candidates. One of the possible candidates for a streptococcal vaccine is the N-terminal region of M protein, which is known to provoke protective immunity. Antibodies to this region are not known to cross-react with human tissue. Nevertheless, the existence of a large number of emm types causes an obstacle in developing effective vaccines. To date, a total of 117 validated emm types have been documented (18). In addition, new ones are being reported continuously so that the number has now reached more than 225 distinct types (see http://www.cdc.gov/ncidod/biotech/infotech_hp.html). Hence, a vaccine targeting this highly variable region of M protein needs to be multivalent, consisting of several types. Currently, such multivalent vaccines composed of the most common emm types in Australia and United States are in development (9, 20, 23).
Streptococcal diseases and their complications are endemic in the tropics (10, 34). In Ethiopia, up to 60% of all hospital admissions of cardiac cases were reported to have a rheumatic origin (14). It has been noted for several years that a difference in M-type distribution exists between the tropics and the temperate regions, since antisera produced against strains from Europe and United States did not recognize large proportions of isolates from the tropics. This implies that a multivalent vaccine targeted against the most common emm types in other part of the world may not be effective in Africa. We sought here to survey the genetic diversity of GAS from Ethiopia by using emm gene sequence analysis and to understand better the epidemiology of this important pathogen in a country where complications resulting from streptococcal infections are still common. A total of 217 GAS isolates obtained from Ethiopian children with various streptococcal diseases and healthy throat carriers during a 1-year period in 1990 (38) were examined. This was the first large-scale emm typing investigation from Africa. The findings demonstrated divergent features of GAS epidemiology in this region.
| MATERIALS AND METHODS |
|---|
|
|
|---|
emm typing. emm typing was performed according to the protocol described by the Centers for Disease Control and Prevention (CDC; http://www.cdc.gov/ncidod/biotech/strep/protocols.html), with some modifications. Enzymatic digestion of bacterial cells to prepare chromosomal DNA as recommended by CDC was omitted. Instead, DNA templates were prepared by boiling bacterial suspensions in distilled water. Briefly, about half a loopful of bacterial cells were picked from an overnight growth on blood agar plates and suspended in 100 µl of distilled water. The suspension was then boiled for 2 min and used for PCR immediately or stored at 20°C until used. Primers 1 and 2 as described by the CDC (5'-TAT TCG CTT AGA AAA TTA A-3' and 5'-GCA AGT TCT TCA GCT TGT TT-3') were used for amplifying the N-terminal region of emm gene. PCR reagents were from AmpliTaq Gold (Applied Biosystems), and the PCR mixture was according to the manufacturer's instructions. Amplification was performed on a PCR thermal cycler (GeneAmp*, PCR System 9700; Applied Biosystems) using the cycle parameters given on the CDC website. Amplification products were purified with JetQuick spin column technique (Germond) according to the manufacturer's instructions. PCR products were then run on the gel to ensure the quality and to estimate the concentration of the product for sequencing reaction.
Primers emmseq2 (TATTCGCTTAGAAAATTAAAAACAGG) or primer 1 were used for sequencing the PCR products using BioDye terminator cycle sequencing ready reaction kit (version 2.0; BioSystems). Primer 1 was used when sequencing with emmseq2 did not give good results. Sequencing reaction mixtures were prepared according to the instructions provided with the kit, and the cycle parameters were 96°C for 1 min for initial denaturation, followed by 25 cycles of 96°C for 10s, 50°C for 5s, and 60°C for 4 min and a holding temperature of 4°C. Sequencing products were purified by using the ethanol sodium acetate precipitation and subjected to automated sequence analysis on an ABI Prism 310 genetic analyzer. The Sequencher genetic software program version 3.0 was used to edit the sequences. The 5' end of the sequences were compared to sequences in the database available at the CDC website (http://www.cdc.gov/ncidod/biotech/strep/strepblast.htm). Sequences that did not find a match in this database were checked for similarity with the published sequences in the GenBank database (http://www.ncbi.nlm.nih.gov/BLAST/). Sequences that were unidentifiable through these databases were sent to the CDC for verification and were assigned new sequence types or subtypes.
emm pattern. emm pattern for the isolates was predicted from the published information of McGregor et al. (30). The emm pattern, which is based on differences in the chromosomal arrangement of the emm and emm-like gene family, has been implicated as a genetic marker for tissue site tropism of GAS strains (6, 33). Since isolates of a given emm type usually display the same emm pattern (30), it is possible to make inferences with a high degree of reliability from the published data.
Tests for significance. The level of significance was determined by calculating the P value using the chi-square test.
Nucleotide sequence accession number. The emm gene sequences for the new types can be found in the EMBL database under the respective accession numbers given in Table 1, as well as at the CDC website. The sequences for the new subtypes were deposited in the CDC streptococcal database (http://www.cdc.gov/ncidod/biotech/strep/strepblast.htm).
|
| RESULTS |
|---|
|
|
|---|
|
emm type versus acute rheumatic fever. Six different emm/st types were detected among the seven ARF cases in the present study. These GAS types were st2940, emm18, stD432, st62, emm74 (two isolates), and emm114. Interestingly, three of them (42.9%) belonged to st types. All except type st2940 were isolated from throat samples. It is not possible to discriminate whether these isolates were in the carrier state or whether they were actually responsible for triggering the rheumatic fever. However, it is possible that st2940 could have triggered rheumatic fever because it was isolated from a skin lesion in a patient who had healing lesions all over her body when admitted to the hospital. In temperate regions rheumatic fever is usually associated with throat infection, but available data indicate that GAS skin infection could be more important in causing rheumatic fever in the tropics (5, 10, 29). Based on decades of epidemiological observations, GAS serotypes M1, 3, 5, 6, 14, 18, 19, and 24 were known to be associated with rheumatic fever in the temperate regions (34). Of these rheumatogenic types, only type emm18 was represented among emm types isolated from the rheumatic fever cases in the present study. It is worth mentioning that types emm1 and emm18 were among the 12 most common emm types, and three more of the classical rheumatogenic typesemm6, emm5, and emm19were also represented among the present GAS collection. Therefore, despite the circulation of the so-called rheumatogenic strains among the general GAS population in Addis Ababa, emm types not implicated with rheumatic fever in temperate regions, were isolated from rheumatic fever cases in the present study.
emm type versus AGN. Among the 16 GAS isolates from AGN patients, 15 different emm/st types were detected (Table 2). These were emm1.2, emm18, emm25, emm55, emm74, emm89, emm95, st206, st212, st221, st3757, st62, st6737, stg653, and stL1376. Most of them, 87.5% (14 of 16) were obtained from skin lesions. Nine of the sixteen isolates (56.3%) belonged to st sequence types. Epidemiological surveys from Europe, the United States, and the Caribbean islands have associated M serotypes 2, 4, 12, 15, 25, 49, 55, 56, 59, 60, and 61 with AGN (7, 13). Of these, only types emm25 and emm55 were represented among the AGN isolates in the present study. It is interesting that emm12, which is the most common isolate in our collection, was not associated with AGN. Moreover, type M49, which is commonly referred to as nephritogenic, was not isolated from the AGN cases in the present study. Two of the three GAS isolates with atypical GAS sequence type, stg653 and stL1376, were associated with AGN. The findings clearly indicate that types other than what have been reported elsewhere as nephritogenic are more important in causing AGN in this region of the world.
emm type versus tonsillitis and healthy carrier state. Thirty-three distinct emm/st types were detected among the 57 GAS strains isolated from tonsillitis cases (Table 2). Thirteen of these were represented by 2 or more isolates, and they comprised 64.9% (37 of 57) of the tonsillitis isolates. The most frequent emm types isolated from tonsillitis cases were emm12, emm1, emm71, and emm25. Three of theseemm1, emm12, and emm25have been among the most frequently isolated GAS strains from tonsillitis cases in Europe and the United States (1, 8, 15). A total of 49 emm/st types were detected among the 90 isolates from throat cultures of healthy carriers. Twelve of these were represented by three or more isolates and comprised 50% (45 of 90) of the total isolates. Two new sequence types, st62 and st463, were among these 12 isolates. The four most common types among isolates from the throat of healthy carriers were emm12, emm18, emm8, and emm22. Of the 57 GAS isolates from tonsillitis cases and the 90 isolates from the throats of healthy carriers, 10 (17.5%) and 16 (17.7%) isolates, respectively, belonged to st types. These levels are significantly lower (P < 0.01) compared to the proportion of st types among AGN (9 of 15 [56.3%]) and ARF (3 of 7 [42.9%]) isolates.
emm types versus skin and throat.
The concept of distinct throat and skin emm types has been widely accepted. M protein serotypes, such as M types 1, 3, 4, 5, 6, 12, 14, 18, 19, and 24 of S. pyogenes, were found to be associated with throat infection (34), while M serotypes such as 2, 49, 57, 59, 60, and 61 are associated with impetigo (13). The number of isolates of each emm type in the present study is not sufficient enough to make statistical correlations on tissue specificity. However, it is worthy to note that a number of emm types with multiple isolates (
3)emm1, emm6, emm8, emm12, emm18, emm25, emm26, emm49, emm71, emm75, emm81, emm116, and st463were isolated from the throat only. Two emm types with three isolates each, emm80 and st212, were associated with skin origin only.
emm pattern versus disease. The GAS population was also analyzed for emm pattern distribution, a genetic marker for tissue preference (6, 33). Patterns A to C have been associated with throat, pattern D is associated with skin, and pattern E is known to have no tissue preference (6). Furthermore, pattern D strains have caused higher skin pathology compared to strains with emm patterns A to C in the human mouse skin model (33). The emm pattern of 183 of 217 (84.3%) isolates in the present study was predicted (Table 3) based on the published information from McGregor et al. (30). These 183 isolates belonged to 63 different emm/st types. The emm pattern for 32 (14.7%) of the isolates, belonging to 15 emm/st types, was not available, because these types were not included in the report of McGregor et al. In the overall GAS population in the present study, emm pattern E was isolated more frequently (38.2%), followed by pattern D (28.1%) and the least common were patterns A to C (17.9%). Patterns A to C were strongly associated with throat (P < 0.01), whereas the frequency of emm pattern D strains did not differ significantly among our skin and throat isolates (Table 3). The strong association of emm pattern A-C strains with the throat is in agreement with a previous report from temperate regions (6). On the other hand, our observation of the lack of association of emm pattern D with skin is in contrast to what has been previously reported (5, 6). The distribution of the three patterns among isolates from symptomatic throat infection and asymptomatic throat carrier state was not statistically significant. Of 57 isolates from tonsillitis cases, 16 carried the genetic marker for skin preference, the emm pattern D. Among the ARF isolates the emm pattern D was overrepresented, with 57% (4 of 7) of the isolates. This is in contrast to so-called rheumatogenic strains from the temperate regions, which belonged to emm patterns A to C (6). Evaluation of AGN isolates with respect to emm pattern could not be made because emm patterns of 50% of the isolates from the AGN had not been determined.
|
| DISCUSSION |
|---|
|
|
|---|
The number of distinct emm/st types, 78, detected among the present collection of GAS strains is much higher than has been found in several emm typing reports from other countries, where larger numbers of isolates collected over a longer period of time were screened (5, 12, 16, 31, 35, 39). In Japan only 29 emm/st types were detected among 906 clinical isolates collected from 1990 to 1999 (35). In Mexico, only 31 emm types were detected among 423 isolates collected from symptomatic pharyngeal specimens from 1991 to 2000 (16). In a population-based study among the Australian aboriginal population, only 31 distinct types were reported among 141 isolates collected from the skin and throats of asymptomatic cases over a 25-month period (5). Among 400 isolates collected over 2 years period from 24 hospitals in Israel, 59 types were detected (31). The more than 16,000 isolates collected from various clinical specimens over a period of 11 years in the United Kingdom (12) were not as diversified as the GAS collection from Ethiopia. In a nationwide survey in Canada, 54 M serotypes were reported among 4,760 GAS isolates submitted to the national center for streptococci from 1993 to 1999 (39). In Spain only 30 different emm types were detected among 614 pharyngeal isolates collected from eight different hospitals over a 4-year period (1). Although a clear reason for the relatively higher heterogeneity observed among the Ethiopian isolates is not apparent, it may partially be explained by the diversity in the sources of the specimens. In contrast to many reports on emm typing surveys in which the isolates were obtained from either clinical samples or asymptomatic cases, the isolates in the present study were obtained from both clinical and asymptomatic cases, as well as from throat and skin sources. It may also be possible that the GAS population in this region is under some strongly diversifying natural selection pressure.
The GAS collection included in the present study was obtained from a single city: Addis Ababa. It should be noted, however, that Addis Ababa is the capital city of Ethiopia, a cosmopolitan city where a high influx of people from the countryside takes place. In addition, during the sampling period there was an increased migration of people toward Addis Ababa mainly from the northern part of the country due to the civil war that was taking place. Thus, isolates in the present study may represent GAS populations from a larger geographic area in Ethiopia.
Since the introduction of the sequence typing method of GAS based on the heterogeneity of the 5' end of the emm gene (4, 25), several previously undocumented new types have been detected. The number of distinct emm/st types has more than doubled in the last few years, and currently the CDC database contains over 225 distinct emm/st types. In the present study 25 isolates (11.5%) of the isolates belonged to 10 previously unrecognized sequence types. The detection rate of undocumented types varies from country to country. In general, more new types were reported from Malaysia (24), Thailand (32), Brazil (36), the United States (3), and Australia (5) compared to those reported from European countries. It is interesting that no new emm type was detected among 133 isolates that were nontypeable by serotyping in Israel (31). The number of newly discovered types among the Ethiopian isolates is comparable to findings reported from Malaysia, Brazil, and Thailand (24, 32, 36).
Poststreptococcal sequelae, ARF and AGN, remain frequent in the tropics, but epidemiological data on GAS dynamics here are still inadequate compared to the temperate regions. From the scanty information available it has been speculated that there is a contrasting feature of GAS epidemiology between the temperate and tropical climate (5, 10, 28, 29). Based on a 1-year study, our findings depict a distinctive pattern of GAS types associated with poststreptococcal complications. The predominance of st types among ARF (42.9%) and AGN (56.3%) isolates in the present study despite the presence of the classical rheumatogenic and nephritogenic types in the general GAS population clearly implies the different nature of GAS types involved in poststreptococcal complications in the region. Moreover, in contrast to what was observed in the temperate regions, most (57.3%) isolates from ARF cases in the present study belonged to emm pattern D, a genetic marker for skin preference (6, 33). The classical rheumatogenic strains from the temperate regions belonged to emm pattern A-C and were throat isolates. Most (six of seven [85.7%]) ARF isolates in the present study were obtained from throat cultures. However, since more than half of them carry the genetic marker for skin preference, emm pattern D, it is likely that the primary site of colonization could be the skin, with the throat being a secondary site of infection. In temperate regions it has been widely accepted that rheumatic fever follows throat infection by emm pattern A-C GAS strains. On the other hand, in the tropics skin infection rather than throat infection was linked to rheumatic fever based on the fact that GAS skin infection rates were far more common and throat carrier rates were lower in the tropics (5, 10, 29). The throat healthy carrier rate among children in Ethiopia (38) was, however, comparable (i.e., 17%) to what has been reported for the temperate regions. Although our results could not substantiate the link between skin infection and rheumatic fever, they strongly suggest the importance of GAS strains with the genetic marker for skin preference. Whether rheumatic fever follows infection of the skin or the throat by the pattern D strains remains to be explored.
A considerable proportion (16 of 57 [28%]) of tonsillitis-associated GAS isolates in the present study carry the skin preference genetic marker, emm pattern D. This figure is much higher compared to reports from Italy (15), Spain (1), and Germany (8), where fewer than 1% of tonsillitis-associated strains had the emm pattern D. It has been noted for several years that the symptoms of tonsillitis in tropical and subtropical climates are relatively milder or subclinical compared to tonsillitis in temperate regions (10, 28). The difference in the clinical manifestation of streptococcal tonsillitis between the tropics and temperate regions may be due to the higher prevalence of emm pattern D strains causing tonsillitis in the tropics, as demonstrated in the present study.
The highly diversified nature of the GAS population in Ethiopia challenges the application of a multivalent vaccine composed of the N-terminal region of the most common emm types. A multivalent vaccine composed of 26 M protein N-terminal region was anticipated to protect ca. 90% invasive GAS infections in the United States (23). Of the 26 emm types included in this multivalent vaccine, only 15 (57.7%) were detected among the GAS collection in the present study (Table 4). In theory, this vaccine would prevent only 31% (68 of 217) of infections in Addis Ababa. In addition, 6 (50%) of the 12 most frequently isolated emm typesemm74, st62, emm25, emm71, emm112, and st463in the present study are not included in the vaccine. Thus, the 26 emm multivalent vaccine, which is basically designed for the United States population, will be ineffective in preventing GAS infection in the Ethiopian population. Designing an effective multivalent vaccine based on the N-terminal region of M protein for regions such as Ethiopia, where the GAS population is highly heterogeneous, the dynamics of streptococcal infections is poorly understood, and skin infections may be more important than throat infection would be challenging. Based on the observations made in the present study, a vaccine carrying at least 43 different emm type-specific epitopes would be required to cover ca. 80% of GAS infections in Addis Ababa. There is also the concern that upon the introduction of such a vaccine the once-rare emm types may eventually replace the dominant emm types and may become important in causing infections. Thus, there will be a need for active surveillance, and a change in the composition of a vaccine may be required on a regular basis. In view of these facts, alternative broad-spectrum GAS vaccines using part of conserved region of M protein or other antigens (11, 26, 27) need to be promoted. GAS vaccine research thus far has mainly aimed at attaining protective immunity at the mucosal level, so as to prevent GAS colonization of the throat. With the possible link between skin infection by GAS and ARF in the tropics, consideration should be given to antigens that have significance in skin colonization and that would induce protective immunity at the portal of entry.
|
| ACKNOWLEDGMENTS |
|---|
We thank Bernard Beall from Centers for Disease Control and Prevention, Atlanta, Ga., for reviewing the sequences and assigning names to the new types and subtypes detected here.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|